| Methods |
4‐week single‐blind placebo phase; inclusion criteria= sitting DBP 95‐115 mm Hg after 2 and 4 weeks of placebo therapy, with the two readings not differing by more than 7 mm Hg; no more than 30% of patients enrolled could have been black; 12‐week double‐blind treatment, 6‐week fixed dose therapy, with BP measured at 3‐week intervals, titrated to response at week 6 |
| Participants |
Losartan 50 mg: n=250(161 males,89 females); mean age=54.1 years; baseline DBP=102.2 mm Hg;
Placebo: n=116(74 males,42 females); mean age=53.8 years; baseline DBP=101.3 mm Hg |
| Interventions |
Losartan 50 mg once daily;
Placebo |
| Outcomes |
Change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
Used week 6 BP data only; BP change reported, DBP SD of change reported only, endpoint BP reported, endpoint DBP SD reported only, baseline SD not reported; imputed overall trial mean SBP SD of change; DBP data from Table 2 and SBP data from Figure 2, p. 38; Jadad score=4; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
